Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics develops small-molecule oncology drugs designed to act through both targeted pathways and immune mechanisms, advancing multiple programs through clinical trials — a therapeutic strategy attempting to escape the crowding in single-target cancer medicine.

The oncology landscape: crowding and segmentation

Cancer drug development is one of the most populated fields in biotechnology. Oncology offers large patient populations, genuine medical need, and pricing power that attracts hundreds of companies and billions in capital. But success rates are low — the majority of cancer drugs fail in clinical trials — and the field has become fragmented by mechanism. Checkpoint inhibitors dominate immunotherapy. Kinase inhibitors and other targeted agents address specific mutations. CAR-T cell therapy has carved out space in hematologic cancers. The landscape has little room for marginal innovations and punishes drugs that work in a single cancer type or mechanism.

Tempest Therapeutics positions itself as a company trying to escape this crowding by combining two mechanisms in a single molecule: direct targeting of a cancer-relevant pathway, plus immune activation that enlists the patient’s own immune system to kill tumor cells. The theory is that dual-action drugs might work where single-mechanism agents hit resistance or insufficient efficacy.

TPST-1120: the lead program

Tempest’s most advanced program is TPST-1120, a small-molecule agonist of the nuclear receptor PPARα (peroxisome proliferator-activated receptor alpha). The drug is intended to kill cancer cells directly by activating PPARα signaling, but also to modulate the immune environment around the tumor — shifting immune cells toward anti-tumor activity and away from suppression.

TPST-1120 is being studied in hepatocellular carcinoma, the most common form of liver cancer. The company published data from REDEEM-1, a Phase 1/2a trial, showing the drug in combination with sorafenib (an approved HCC therapy) and with pembrolizumab (an immune checkpoint inhibitor). Results included responses, and the data prompted Tempest to advance into a pivotal Phase 2b trial comparing TPST-1120 combination therapy against standard of care in first-line HCC. Regulators in China have cleared the company to proceed with a pivotal trial there as well, a significant approval given the size of the HCC patient population in the region.

If TPST-1120 succeeds, it could become a standard treatment option in HCC, a cancer with limited effective therapies and high unmet need. Hepatocellular carcinoma is typically advanced at diagnosis and carries poor prognosis, so even modest improvements in survival or time-to-progression attract serious interest from oncologists and patients. The market opportunity is substantial.

TPST-1495 and the EP2/EP4 program

Tempest’s second major program targets two immune-modulating receptors, EP2 and EP4 (prostaglandin receptors). TPST-1495 is designed to act as an antagonist of these pathways, blocking signals that suppress anti-tumor immune activity. The rationale is that blocking EP2/EP4 signaling should enhance the immune response against tumors, similar to how checkpoint inhibitors work but through a different mechanism.

This program is earlier stage than TPST-1120, in Phase 1/2 development, with trials ongoing in multiple cancer types. The company is studying the drug as a monotherapy and in combination with approved agents. If successful, an EP2/EP4 antagonist could address a large market — many solid tumors and hematologic cancers might benefit from immune augmentation through this pathway. However, the mechanism is still being validated, and competition in immune-oncology is intense.

TPST-2003 and CAR-T assets

Tempest acquired the CAR-T assets of Factor Bioscience, adding a third therapeutic direction to the company’s pipeline. CAR-T cells are engineered immune cells programmed to recognize and kill cancer cells bearing specific antigens. The field is well-established but competitive, with major companies dominating early successes in multiple myeloma and lymphoma.

Tempest’s CAR-T program, TPST-2003, is being studied in relapsed/refractory multiple myeloma, a difficult-to-treat cancer. Early data from a Phase 1/2a trial (REDEEM-1) showed a complete response rate of 100% in six evaluable patients, a remarkable result if it holds. However, early-stage trial data can be misleading — small patient numbers and selection bias can distort apparent efficacy. Success in later-stage, larger trials would be required to establish whether TPST-2003 offers a genuine advantage over existing CAR-T therapies.

The competitive moat: tenuous at early stage

Tempest operates in the earliest stages of drug development. The company holds patents on its molecular targets and approaches, but patents in oncology are not a durable moat until a drug is approved and generating revenue. Every program faces the risk of clinical failure, regulatory rejection, or manufacturing challenges. Most clinical-stage drugs fail.

If TPST-1120 is approved and becomes successful in HCC, Tempest would gain some market position and cash flow, which could fund later programs. Patent protection on the drug would provide a period of exclusivity before generics appear. But approval is uncertain, and even if successful, competitors could develop alternative PPARα agonists or approach HCC through different mechanisms.

For now, Tempest’s competitive position is determined by the quality of its science, the depth of its clinical data, and the quality of its trials. The company must generate evidence that its dual-mechanism approach works better than single-mechanism alternatives or standard of care. That evidence will come from trials over years. Until then, the company is in a race against cash burn and scientific risk.

Cash position and financial runway

Tempest ended 2025 with approximately 7.7 million dollars in cash, down sharply from 30.3 million in 2024. The company raised roughly 8.5 million through registered direct offerings. This is a significant depletion rate, suggesting cash runway of perhaps a year or so without additional capital infusions. For a clinical-stage company, this is a near-term constraint. Tempest will need to raise more capital or achieve significant licensing or partnership deals to continue operations.

What investors watch

Progress in the TPST-1120 HCC trial is the primary catalyst. Positive interim data or trial completion would be major news. The company’s ability to secure partnerships or licensing deals — especially with larger pharma companies interested in co-developing or commercializing successful programs — also matters. Cash position and burn rate are critical; any sign that the company cannot fund operations without dilutive capital raises is a warning. And competition: as other dual-mechanism or immune-oncology drugs advance, Tempest’s relative position in a crowded field will become clearer.